

Nanexa signs evaluation agreement with a large global pharmaceutical company

Nanexa AB (publ) today announced that the company has signed a Material Transfer and Feasibility Study Agreement with one of the largest global pharmaceutical companies for the evaluation of Nanexa's drug delivery system, PharmaShell®, in a depot formulation of a monoclonal antibody.

The study aims to develop a long-acting formulation of one of the pharmaceutical company's monoclonal antibodies, utilizing the PharmaShell system.

"Adding this project to our portfolio of collaborative ventures is truly gratifying, especially as we leverage our PharmaShell system in the field of monoclonal antibodies, an area we believe holds immense potential. It's, of course, equally thrilling for Nanexa to initiate a collaboration with this large pharmaceutical company. We eagerly anticipate commencing our work shortly, with the objective of producing results that can serve as the foundation for a more comprehensive development program," said David Westberg, CEO of Nanexa.

The agreement regulates, among other things, details of what shall be investigated, clarification regarding patent rights, and a determined fee to Nanexa for this evaluation.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Press Release
29 November 2023 08:30:00 CET



Attachments

[Nanexa signs evaluation agreement with a large global pharmaceutical company](#)